BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

Genfit’s PPAR agonist fails to resolve NASH Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) fell $10.88 (49%) to $11.22 in after-hours trading Monday after reporting that dual PPARα/δ agonist elafibranor missed the primary endpoint of the Phase III...
BioCentury | Jan 24, 2018
Emerging Company Profile

D over L for diabetes

ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without courting the broad-spectrum immunosuppression of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the...
BioCentury | Dec 1, 2016
Targets & Mechanisms

Not a peripheral story

By sourcing T cells directly from the pancreatic islets of Type I diabetes patients, rather than the standard method of taking blood samples, an academic team has provided an unprecedented view into the molecules that...
BioCentury | Mar 7, 2016
Company News

Primerdesign, Novacyt deal

Novacyt will acquire fellow diagnostic company Primerdesign for L5 million ($7.1 million) in cash and L4.9 million ($7 million) in Novacyt shares. Primerdesign is also eligible for sales milestones of up toL2.5 million ($3.6 million)...
BioCentury | Jul 29, 2013
Product Development

Tolerion's second wind

Armed with positive Phase IIa data in Type I diabetes, Tolerion Inc. is now seeking funding for a second go at developing a selective immunomodulatory approach that previously failed in multiple sclerosis. In 2011, Tolerion...
BioCentury | Jul 1, 2013
Clinical News

TOL-3021: Phase II data

A blinded, dose-escalation Phase II trial in 80 adult Type I diabetics showed that all doses of once-weekly intramuscular TOL-3021 for 12 weeks improved C-peptide levels, a marker of pancreatic beta cell function, relative to...
BioCentury | Jun 27, 2013
Clinical News

Tolerion reports Phase II data for Type I diabetes vaccine

Tolerion Inc. (Portola Valley, Calif.) said all doses of once-weekly intramuscular TOL-3021 for 12 weeks improved C-peptide levels, a marker of pancreatic beta cell function, relative to placebo in a Phase II trial to treat...
BioCentury | Jun 28, 2010
Clinical News

TOL101 regulatory update

FDA granted Orphan Drug designation for Tolera's TOL101 to treat Type I diabetes in patients ages 16 years or younger with preserved pancreatic beta-cell function. The mAb against alpha beta T cell receptor is in...
BioCentury | Jan 11, 2010
Emerging Company Profile

Tolera: Delta Force Improves Tolerance

Corporate Profile Tolera Therapeutics Inc. is developing a mAb against the alpha beta T cell receptor designed to improve upon the safety and tolerability of Genzyme Corp. 's Thymoglobulin , the market-leading antibody for induction therapy...
BioCentury | Apr 20, 2009
Clinical News

TOL101 regulatory update

FDA granted Orphan Drug designation for Tolera'sTOL101 to prevent acute rejection of solid organ transplantation. The mAb against T cells is in Phase II testing for the indication. Tolera Therapeutics Inc. , Cleveland, Ohio Product: TOL101...
Items per page:
1 - 10 of 10